Zanubrutinib

Near Add Your Location

Accepting patients

PRT2527

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies
Learn more
  • Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
  • Phase 1